Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HIV Vaccine N332-GT5 gp140 Adjuvanted With SMNP in Healthy Adults
NCT06033209Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of N332-GT5 gp140 and SMNP in human immunodeficiency virus infection (HIV) (15 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local reactogenicity signs and symptoms at 1 year, Systemic reactogenicity signs and symptoms at 1 year and 8 more. Started Nov 2023; status: completed.
02
Drugs
N332-GT5 gp140SMNP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06033209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033209.